ASCO GU 2019 Prostate Cancer

REVIEW UroToday

Viewing 1-20 of 47 articles

ASCO GU 2019: Value-Based Decision-Making for Castrate-Sensitive Prostate Cancer

ASCO GU 2019: Pembrolizumab in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: PROSPER: Comparing Perioperative Nivolumab versus Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy

ASCO GU 2019: Prevention of Symptomatic Skeletal Events with Denosumab: REDUSE Trial

ASCO GU 2019: Enzalutamide and ADT with Salvage Radiation in Men with High-Risk PSA Recurrent Prostate Cancer: The STREAM trial

ASCO GU 2019: A Comparison of Fluorocholine-PET/CT and Conventional Imaging in Prostate Cancer

ASCO GU 2019: Transitional Surrogate Endpoint for Survival in Phase II Trials for mCRPC - Assessment of Circulating Tumor Cell Number

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

ASCO GU 2019: TALAPRO-2: A Two-Part, Placebo-Controlled Phase III Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: The P-Value Debate: Lower Them or Leave Them?

ASCO GU 2019: Results of a 50 Patient Single-Centre Phase II Prospective Trial of Lutetium-177 PSMA-617 Theranostics in mCRPC

ASCO GU 2019: Oligometastatic Disease: Tumor Board - Medical Oncologist Perspective by Silke Gillessen, MD

ASCO GU 2019: A Phase II Trial in Progress: Pamiparib, an Investigational PARP Inhibitor, in Patients with mCRPC and a Circulating Tumor Cell Homologous Recombination Deficiency Phenotype or BRCA Defects

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Radiation Oncologist Perspective by Gert de Meerleer, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board, A Radiation Oncologist Perspective by Bridget Koontz, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Medical Oncologist Perspective by Michael Morris, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Urologic Oncologist Perspective by Edward Schaeffer, MD

ASCO GU 2019: The CHEIRON Study - A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide versus Docetaxel as First-Line Chemotherapy for Patients with mCRPC

ASCO GU 2019: Updated Analysis of Progression-Free Survival with First Subsequent Therapy and Safety in the SPARTAN Study of Apalutamide in Patients with High-Risk nmCRPC

ASCO GU 2019: Pembrolizumab Plus Olaparib Treatment for Docetaxel-Pretreated mCRPC Patients - KEYNOTE 365 Cohort A

1
2
3